Enzo Biochem Says Breakthrough Preclinical Study Identified Cells and Developed Approach to Treat Immune Mediated Colitis.Business Editors/Health & Medical Writers FARMINGDALE, N.Y.--(BUSINESS WIRE)--Nov. 5, 2002 Enzo Biochem, Inc. (NYSE NYSE See: New York Stock Exchange :ENZ) in a paper published at the meeting of the American Association for the Study of Liver Diseases, reported that in preclinical studies preclinical studies, n.pl a term used to describe research done before a clinical study. May be laboratory or epidemiologic research. it had identified cells alleviating immune mediated colitis and developed an approach to its treatment. In the study, Enzo researchers were able to alleviate the colitis symptoms by training or educating in vitro in vitro /in vi·tro/ (in ve´tro) [L.] within a glass; observable in a test tube; in an artificial environment. in vi·tro adj. In an artificial environment outside a living organism. NKT NKT New Kadampa Tradition NKT Natural killer T-cells (lymphocytes) NKT Nederlands Keuringsinstituut voor Telecommunicatieapparatuur (Dutch Regulatory Branch) NKT Non-Kinetic Technology NKT Northern Kentucky Transit, Inc. cells obtained from one mouse and then transferring the cells to other mice having the disease. The study was able to achieve the precise identification of the cells that cause the event of immune mediate colitis, thus contributing an important insight into the causes of the disease. It also resulted in the ability to develop an approach to the treatment of immune mediated colitis. The development was reported at the proceedings of the American Association for the Study of Liver Diseases, meeting in Boston, MA, in a report entitled "Adoptive Transfer adoptive transfer the transfer of cells, commonly lymphocytes from an immunized individual, to a non-immune recipient. of Ex Vivo ex vivo /ex vi·vo/ (eks´ ve´vo) outside the living body; denoting removal of an organ (e.g., the kidney) for reparative surgery, after which it is returned to the original site. Immune Programmed NKT Lymphocytes Alleviate Immune Mediated Colitis" by Yaron Ilan, MD, head of the Liver Unit, in the Department of Medicine, Hadassah-Hebrew University Medical Center, Jerusalem, Israel. Other collaborators included Enzo Biochem scientists Elazar Rabbani, Ph.D., Dean Engelhardt, Ph.D., and Barbara Thalenfeld, Ph.D. "We have managed to identify those cells which perform as a traffic cop, if you will, having the ability to direct the cells to alleviate the immune mediate colitis," Dr. Dean Engelhardt, Executive Vice President said, "Our breakthrough results strongly suggest that this subset of lymphocytes play an important role in regulation of immune mediated disorders." About Enzo Enzo Biochem is engaged in the research, development and manufacture of innovative health care products based on molecular biology molecular biology, scientific study of the molecular basis of life processes, including cellular respiration, excretion, and reproduction. The term molecular biology was coined in 1938 by Warren Weaver, then director of the natural sciences program at the Rockefeller and genetic engineering techniques, and in providing diagnostic services diagnostic services, n.pl the imaging and laboratory capabilities available for determining the cause of an illness. to the medical community. The Company's proprietary labeling and detection products for gene sequencing and genetic analysis, with approximately 200 patents worldwide, are sold to the life sciences market throughout the world. The Company's therapeutic division is conducting clinical trials of its proprietary gene medicine for HIV-1 infection and clinical trials of its proprietary immune regulation medicines for hepatitis B Hepatitis B Definition Hepatitis B is a potentially serious form of liver inflammation due to infection by the hepatitis B virus (HBV). It occurs in both rapidly developing (acute) and long-lasting (chronic) forms, and is one of the most common chronic and hepatitis C infection and for Crohn's Disease. The Company also holds a patent covering a method and materials for correcting point mutations or small insertions or deletions of genetic material that would allow for editing and correcting certain abnormalities in genes. Except for historical information, the matters discussed in this news release may be considered "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this press release. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion